The US Drug Supply Chain: Safety Must be Paramount - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The US Drug Supply Chain: Safety Must be Paramount
Holding product and supply-chain security to the highest standards is crucial for the future.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 97-98


Robert Billings
Extraordinary commitments by the pharmaceutical industry and the US Food and Drug Administration aim to ensure that prescription drugs sold in the US and throughout the supply chain are completely safe. Both FDA and industry continuously pursue every means available to help guarantee that the medicines patients and practitioners receive are of the highest quality.

As FDA Commissioner Margaret Hamburg noted in February 2010 at the Center for Strategic and International Studies, all people of the world deserve access to safe food and quality medical care. She also noted that FDA is a critical player, domestically and internationally in promoting and protecting the health of the public.

With the contaminated heparin incident in 2008, it became apparent that those individuals intent on deliberately adulterating drug products were finding sophisticated means of operating. And while such incidents are rare, the realities of a globalized pharmaceutical marketplace have resulted in challenges and opportunities for industry and FDA to develop systems to protect the quality of the materials used in drug manufacturing and the security of products as they move from the original source to the end user. Approximately 4 billion prescriptions were dispensed in the US in 2009, according to IMS Health. That number equates to several billions of tablets, capsules, liquids, injectables, inhalation units, and other dosage forms, and the active ingredients used in making them, moving through the supply chain. However, the Generic Pharmaceutical Association (GPhA) believes that careful vigilance by FDA, manufacturers, and supply-chain stakeholders can keep the prevalence of drug contamination and intentional adulteration low.

Combatting counterfeits

Proactive efforts to protect consumers from counterfeit drugs also must be a priority. Although most drugs, including the generic drugs that account for 75% of all prescriptions dispensed in the US, are seldom targeted by counterfeiters, counterfeit versions of some of the most expensive prescription medicines continue to appear in the marketplace. Many of these counterfeit versions are sold over the Internet with little or no regulatory control. Counterfeit drugs present a significant risk to public health, not only because they are unapproved, but also because they fail to deliver the needed therapeutic effect to the user.

Keeping counterfeit and contaminated drugs out of the US supply requires a dual effort spearheaded by FDA and industry. Only through corporative and coordinated action can the necessary oversight and controls be capable of maintaining drug security. For instance, the new border-control initiative developed by FDA is an excellent endeavor to curtail the incidence of poor standard medicines entering the US from other countries. This program, Predictive Risk-based Evaluation for Dynamic Import Compliance Targeting (PREDICT), encompasses a border-based method that assesses drugs at the point of import. Barcodes on cases of medicines will be scanned at US points of entry and linked to a central database.

As a result, FDA border agents will know immediately whether the producer has a license to ship and sell drugs into the US. If the products do not meet FDA compliance, they will not be allowed passed the borders. For its part, the pharmaceutical industry uses multiple strategies to prevent counterfeit drugs from entering the US supply chain, including comprehensive vender audits, robust controls of the supply chain, monitoring and control of qualified shipping channels to name a few.

Supply-chain and testing controls

Regarding the supply and distribution, manufacturers must continue their robust testing and supplier oversight to ensure that quality is built into the process. Innovator-drug firms operate in a highly regulated environment, and rightly so. Makers of finished dosage forms methodically and meticulously evaluate the plants, manufacturing practices, and quality control capabilities of their suppliers' inactive and active ingredients suppliers.

These company-led assessments provide the foundation for drug-product quality by ensuring that prudent and deliberate steps are taken to eliminate potential contamination or adulteration in distribution channels. Moreover, manufacturers test incoming raw materials for quality, purity, and potency in accordance with FDA-approved analytical methods. The test methods in place are designed to ensure that all active ingredients and other raw materials meet their predetermined quality attributes. Finished-dosage manufacturers also perform sophisticated testing during the manufacturing process that helps to verify that prescription medicines delivered to consumers and patients meet all standards for quality, purity, and potency.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here